Literature DB >> 11477480

Possible association between CTLA4 DNA polymorphisms and early onset type 1 diabetes in a UK population.

R M McCormack1, A P Maxwell, D Carson, C C Patterson, A Bingham, D A Savage.   

Abstract

Linkage and association has been reported between CTLA4 DNA markers and susceptibility to type 1 diabetes in some populations, but not others. We performed case-control and family-based association studies to assess if the CTLA4 A49G and intron 1 C/T polymorphisms were associated with development of early onset type 1 diabetes in the Northern Ireland population. The distribution of A49G and C/T alleles in cases (n = 144) was similar to those observed in controls (n = 307). In contrast, significant distortions in allele transmissions from informative parents to probands were observed for both the A49G (P = 0.02) and C/T (P = 0.01) polymorphisms employing 297 nuclear families. Our results suggest that the CTLA4 gene may play a minor role in the overall genetic predisposition to type 1 diabetes in this UK population.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11477480     DOI: 10.1038/sj.gene.6363749

Source DB:  PubMed          Journal:  Genes Immun        ISSN: 1466-4879            Impact factor:   2.676


  3 in total

1.  CTLA4 is differentially associated with autoimmune diseases in the Dutch population.

Authors:  Alexandra Zhernakova; Peter Eerligh; Pilar Barrera; Joanna Z Wesoly; Joanna Z Weseloy; Tom W J Huizinga; Bart O Roep; Cisca Wijmenga; Bobby P C Koeleman
Journal:  Hum Genet       Date:  2005-07-16       Impact factor: 4.132

2.  The CTLA4 -819 C/T and +49 A/G dimorphisms are associated with Type 1 diabetes in Egyptian children.

Authors:  Hatem Mohamed Saleh; Nestor Rohowsky; Michael Leski
Journal:  Indian J Hum Genet       Date:  2008-09

3.  Common variants on cytotoxic T lymphocyte antigen-4 polymorphisms contributes to type 1 diabetes susceptibility: evidence based on 58 studies.

Authors:  Jingnan Wang; Lianyong Liu; Junhua Ma; Fei Sun; Zefei Zhao; Mingjun Gu
Journal:  PLoS One       Date:  2014-01-23       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.